Trial Profile
Phase II study of low-dose afatinib for elderly patients with non-small cell lung cancer harboring EGFR mutation (based on TDM)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2016
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Aug 2016 Status changed from not yet recruiting to recruiting.
- 24 May 2016 New trial record